The company will not receive any proceeds from the sale of the ordinary shares by the selling shareholders.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid Launches Long-Acting GLP-1 Delivery Platform for Diabetes Market
- PolyPid Approves Key Resolutions at Annual Shareholder Meeting
- Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
- PolyPid price target lowered to $9 from $12 at Roth Capital
- PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial